We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

41 hedge funds and large institutions have $8.19M invested in Albireo Pharma Inc in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

11% more funds holding

Funds holding: 37 → 41 (+4)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

29% less capital invested

Capital invested by funds: $11.6M → $8.19M (-$3.4M)

80% less call options, than puts

Call options by funds: $16K | Put options by funds: $81K

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
1.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
13
Closed
1
Calls
$16K
Puts
$81K
Net Calls
-$65K
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.4M
2
FNYS
First New York Securities
New York
+$520K
3
Group One Trading
Group One Trading
Illinois
+$115K
4
FMA
FNY Managed Accounts
New York
+$61.3K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$35K

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$887K
2
Renaissance Technologies
Renaissance Technologies
New York
-$311K
3
TC
TFS Capital
Pennsylvania
-$136K
4
CC
Cannell & Co
New York
-$69.2K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$27.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAG
26
Private Advisor Group
New Jersey
$22K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$22K +$25.1K +437 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$20K – – –
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$18K -$27.2K -473 -57%
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$15K -$15.3K -267 -47%
BIM
31
BlackRock Investment Management
Delaware
$6K -$57 -1 -0.9%
Morgan Stanley
32
Morgan Stanley
New York
$4K +$517 +9 +13%
Citigroup
33
Citigroup
New York
$3K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$3K +$2.76K +48 +1,600%
SM
35
Sabby Management
Florida
$2.49K +$2.4M +41,740 +520%
PMFA
36
Plante Moran Financial Advisors
Michigan
$2K – – –
Wells Fargo
37
Wells Fargo
California
$2K +$2.64K +46 New
Bank of America
38
Bank of America
North Carolina
$1K -$287 -5 -17%
Creative Planning
39
Creative Planning
Kansas
$1K – – –
MFS
40
MSI Financial Services
Massachusetts
$1K – – –
BA
41
BlackRock Advisors
Delaware
– -$13K -193 Closed
1
2

ALBO Hedge Fund Activity: Q3 2014 in Review

41 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2014, worth a combined $8.19M — down 29% from $11.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ALBO positions and 1 closed out — a net gain of 4 holders — while 10 added to existing stakes and 13 trimmed.

The largest buyer was Sabby Management, adding an estimated $2.4M. The largest seller was William Blair & Company, cutting an estimated $887K.

  • 41 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2014, up from 37 in Q2 2014.
  • Funds reported $8.19M of Albireo Pharma Inc stock for Q3 2014, down 29% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q3 2014 and 1 closed out, a net change of +4 holders.
  • The largest Albireo Pharma Inc buyer in Q3 2014 was Sabby Management, an estimated $2.4M added.
  • The largest Albireo Pharma Inc seller in Q3 2014 was William Blair & Company, an estimated $887K sold.

Based on aggregated 13F filings for Q3 2014.